Introduction
Ovarian cancer remains to be the fifth leading cause of death from cancer in women. The majority of patients have advanced stage disease at diagnosis [1] . Radical surgery and combination chemotherapy have a significant physical impact on patients and coupled with the knowledge of the high likelihood of recurrence and the overall poor prognosis these results in a strong psychological impact. Patients are abruptly confronted with a lifethreatening and life-altering state.
After primary diagnosis and throughout disease trajectory, addressing the information needs is the cornerstone of good supportive care [2, 3] . Comprehensive and clear communication appears to play a major role in well-being of patients and their families by reducing anxiety and depressive symptoms as well as increasing satisfaction [4] [5] [6] . Furthermore, intercultural differences may impact on the reception of information and patients' needs [7] .
The purpose of the present study was to examine patients' needs regarding medical information among women with ovarian cancer in eight different European countries, and to investigate patient's expectations regarding doctor-patient communication.
Methods

Study information
The survey 'Expression III' is a concept of the North-East German Society for Gynecological Oncology (NOGGO) and has been conducted within the European Network for Gynaecological Oncological Trial Groups (ENGOT) and Gynecological Cancer Intergroup (GCIG).
Between December 2009 and October 2012 in Germany, France, Italy, Spain, Austria, Romania, Poland and Belgium, all adult patients with diagnosis of primary or relapsed ovarian cancer were invited to participate once, not including patients, who solely underwent primary surgery. The survey was offered by the participating study sites and by a call posted on the NOGGO homepage. All in-and outpatients could be included independent of any scheduled appointment.
The questionnaire involved 43 items and questions could be answered either as multiple choice, as free text or on a 10-point scale (see supplementary material, available at Annals of Oncology online).
Translated into the respective national language the questionnaire could be either completed directly into a web-based documentation system (Alcedis GmbH, Gießen, Germany) or paper-based, according to patients' choice. The paper questionnaires were sent to the NOGGO study office and entered into the web-based documentation system. The results of the patient population were analyzed, as well as differences between predefined patient cohorts: country of residence; age (<50 years; 50-65 years; >65 years); primary versus recurrent disease; current treatment status (undergoing therapy versus surveillance).
The study was approved by the local national ethic committees. Patients' written informed consent was not deemed necessary as patients remain anonymous and could opt to complete the questionnaire. Table 1 ).
Statistics
More than half (51.6%) of the study population was aware of their FIGO-stage [286 patients (15.6%) initially diagnosed with FIGO I/II, 658 patients (36%) with FIGO III/IV]. Nearly all patients (96.2%) had upfront surgery followed by adjuvant chemotherapy (91.8%). About 989 patients (54%) were on therapy, a majority receiving chemotherapy (see Table 1 ). Patients' perception of therapy
Being asked about their own treatment objectives, 67% stated to hope for full recovery, 40% hoped for no more cancer symptoms and 22% hoped for no loss of life years (see Figure 1 ). Age-Younger participants (50 years) hoped for full recovery (67.8% versus 54.3%, P < 0.001); participants 65 years rather hoped for no more cancer symptoms (42.6% versus 32.0%).
Primary versus recurrent-Significantly more patients with primary disease hoped for full recovery (69.6% versus 50.8%, P < 0.001). Patients with recurrent disease placed their hopes on a less painful course of disease (39.4%) and no loss of life years (27.8%).
Using a 10-point scale, 64% of patients rated the success of therapy better than expected (8) . The median score given for the expected distress caused by side effects, associated with surgery and pain was seven and for nausea and vomiting eight. The lowest median score with a median of six was obtained for the expected extend of exhaustion. Age-Pain was experienced significantly worse by younger patients (50 years, P < 0.001).
Primary versus recurrent-Patients with primary disease gave higher scores regarding the success of therapy (P < 0.001), while patients with recurrent disease experienced side-effects and nausea and vomiting worse (P < 0.001).
Under current therapy-Participants who completed their therapy rated averagely their therapy success higher than participants under current therapy (P < 0.001).
We analyzed which criteria determined the success of therapy. With multiple answers being allowed, 43% stated current wellbeing, 43% measured the success based on feedback of the treating physician and 41% rated the success of therapy on the course of the tumor marker (see Figure 1) . Regarding the importance of the effectiveness and tolerability of the treatment, 77.1% gave maximum points for the need of treatment efficacy, while only 53.9% assigned maximum scores for the importance of tolerability.
Cross-national-The majority of patients from Germany (55.4%), Italy (40.8%) Belgium (39.3%) and Austria (46.2%) evaluated their therapy success on their current well-being, while Polish (77.0%) and Spanish (50.7%) participants relied on the feedback of their treating physician and French (56.7%) and Romanian (50.5%) patients rated the success depending on the course of their tumor marker.
Primary versus recurrent-Significantly more participants with recurrent disease measured therapy success on the course of the tumor marker (50.2% versus 35.7%, P < 0.001).
Under current therapy-52.2% of patients with completed therapy but only 37.2%, patients under current therapy regarded their current well-being as the most important sign for therapy success (P < 0.001).
The three most needed improvements concerning the treatment were (see Figure 1 ):
• Treatment should not result in hair loss (42%).
• More should be done to treat exhaustion (34.5%).
• Treatment should be more effective (29.7%).
Age-Patients 65 years wished significantly more for no hair loss (P < 0.001), while younger patients stated that the treatment should be more effective (P ¼ 0.001).
Primary versus recurrent-Significantly more patients with recurrent disease wished for a more effective treatment (P < 0.001).
Under current therapy-Significantly more participants under current therapy wished for more effectiveness of therapy (P < 0.001).
Information needs
Addressing information needs concerning life expectancy, the majority of the patients wished for an indication as precise as possible (64.6%) or an approximate estimation (22.4%) of survival. About 85% needed detailed information about the possible sideeffects and discomforts during therapy and 86% would have welcomed information on other treatment options as a basis for decision making (see Figure 1) . About 56% wished to receive information on the mechanisms and effects of the received drugs.
Cross-national-About 80% of Austrian participants wanted precise information about life expectancy compared with 27.1% of Polish participants. Over 90% of German patients wished to be truthfully informed about alternative treatment options and to be involved in decision making while 27% of Polish and Romanian patients stated they would feel more insecure receiving this amount of information.
Age-About 89% of participants 50 years were in need of detailed information about discomforts during therapy compared with 79% of participants 65 years (P < 0.001). About 90% of the younger age group preferred to be informed about alternative treatment options while 21% of patients 65 years stated they would feel more insecure receiving this information (P < 0.001).
Primary versus recurrent-More patients with primary disease wanted to be informed as precisely as possible about life expectancy (67.7% versus 59%, P ¼ 0.001), while more patients with recurrent disease did not want to be informed in detail about expected discomforts during therapy (16.9% versus 12.3%, P ¼ 0.014).
Participants' required truthful and complete information regarding the expected timing (40.2%) and nature (35.5%) of deterioration of their general condition, the expected limitation to their social functioning (27.9%) and limited mobility (21%). Additional important questions that have to be answered throughout the course of disease included 'am I receiving the correct therapy' (55%), 'how long do I have to stay in hospital' (20.3%) and 'which abilities am I able to maintain for how long' (25.2%).
Cross-national-In all participating countries, the greatest importance was attached to the question whether the patient is receiving the correct therapy.
Age-Patients 50 years were significantly more in need of detailed information about the course of disease, expected limitations and the level of qualification and experience of the treating physician (P < 0.001). Furthermore younger patients showed more interest in the expected duration of hospitalization (P < 0.001).
Primary versus recurrent-A higher percentage of patients with recurrent disease preferred no detailed information about a negative prognosis (24.5% versus 17.7%, P ¼ 0.001).
Under current therapy-Responders who had completed therapy were in greater need of complete information about possible hospitalization and the experience of the treating physician (P < 0.001).
Overall, 93.4% of the patients felt to be fully informed about their illness and therapy by their treating physician.
Support needs
In the participants' opinion the most support in coping with the illness was received by family members or friends (78.8%), followed by the treating physician (20.6%).
Cross-national-Compared with 8.1% of Italian participants in Romania 46.6% and Spain 34% stated to receive the most support from the treating physician. Romanian patients relied less on family members and friends (53.4%) compared with other participating countries (Italy 87.3%; Poland 85.4%).
The most frequent answer given to the request to propose improvements concerning the involvement in treatment and decision-making was 'a person who has their confidence should be present during conversation between doctor and patient, in which new information is given' (41.5%). The second frequent answer was 'a qualified doctor especially provided for answering patients' question should be easily reachable' (38.4%). Furthermore patients proposed 'initially full information on basis of a therapy roadmap should be explained, followed by further information in small portions' (31.7%).
Cross-national-Compared with 61.5% of German patients only 16% of Spanish patients preferred the presence of a person of confidence during a conversation with their treating physician. The highest request in Spain was for an additional easily accessible doctor, whereas only 17% of French patients regarded an additional doctor as an improvement. Great differences were seen concerning the need of a therapy roadmap (Italy 11.6% versus Poland 70.8%).
Age-Younger patients were in need of a well-explained therapy strategy (<50 years 35.5% versus 65 years 22%, P < 0.001).
Primary versus recurrent-Patients with primary disease showed a higher need of the presence of a person of confidence (44% versus 38%), the possibility to ask specific questions (21% versus 15%, P ¼ 0.001) and an easily reachable doctor (41% versus 36%).
About 37% of respondents stated a patient diary would be their most helpful aid for keeping track of their response to treatment. Patients' greatest demand for documentation was concerning the current treatment (50.5%), the course of the tumor marker (62.6%) and the current medication (60.2%).
Cross-national-Regarding a patient diary we saw a wide variation between the different participating countries. Compared with German participants (58.8%) who welcomed a diary for tracking their course of disease, Spanish participants showed a rather hesitant attitude towards a diary (14.4%).
The majority of patients contact their treating physician first as an information source (86%). About 68% of patients would welcome the opportunity to receive information from an independent expert while only 7.1%, however, knew such a source.
Psychological aspects
When asked to state what they assume to be the main cause of their illness, patients' most commonly replies were environmental factors (29.8%), stress at work (22.7%), stress in the family (20.5%) and individual diet (11.9%).
Cross-national-Compared with 8.9% of Belgian participants, 55.6% of Polish participants blamed environmental factors, while Romanian patients blamed increased stress at work (37.2%) and 22% of German and French patients the stress in the family.
The three most difficult to handle aspects of disease for patients were stated to be the fear of future (43.4%), fear of possible sideeffects (20.5%) and the feeling of powerlessness (19.1%).
The most frequent strategies to the question 'What do you do to help the outcome of your illness' stated by patients were 'fighting the illness and never lose faith' (59.6%), 'following the treating physician's instructions' (58.2%) and 'positive thinking' (56.5%).
Cross-national-While 46% of German patients and 43% of Polish and Romanian patients wanted to eat more healthy for a positive outcome of their disease, only 14% of Belgian patients and 18% of Italian patients planned to alter their eating habits. The majority of Polish patients intended to follow the treating physician's instruction (71.9%) and the majority of German patients had the highest hopes in mentally fighting the illness (73.7%).
Discussion
The primary aim of this study, which is the largest of its kind, was to examine participants' needs and expectations concerning doctor-patient communication and the amount of information patients receive and demonstrates that these topics can be addressed and analyzed in an international study [electronic search until September 2017 in the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL) and Medical Literature Analysis and Retrieval System Online (MEDLINE). Used terms were 'ovarian neoplasms', 'ovarian cancer', 'doctor-patient communication', 'doctor-patient relationship', 'physician-patient communication', 'physician-patient relationship', 'survey' and 'expectation'].
The present questionnaire was not primarily statistically configured to detect cross-national differences; however, the answers of each country were compared. Variability between the responses could be detected. Nevertheless, the results of this study show that patients from different countries of residence cannot be generally categorized regarding their information needs and expectations.
The median age of the study population was slightly lower than the median age of patients with ovarian cancer; probably biased by the preferential use of the Internet survey by younger patients. Nevertheless, we do not believe that this fact would substantially impact the results of the study findings.
Concordant with our results, other studies have also reported that patients with malignant disease have high unmet needs and demands for information and counseling about their disease and consider receiving more information as helpful [8] [9] [10] [11] [12] [13] . Studies show that playing a passive role in treatment decision causes significantly more distress and decrement in quality of life [13] . To further improve addressing needs of patients, future studies should systematically investigate prospectively the impact of cultural influences, expectations and patients' processing of information on their disease. Shared decision making is based on the interaction between physician and patient, while patient's treatment choices are influenced by the level of knowledge and understanding of the disease and therapy [3] . To gain the amount of knowledge needed to be able to make decisions, the physician remains to be the most important and most competent point of contact. The results of our study show similar to previous studies that the physician's role is an essential not only as a source of information but also provides psychological support as well as symptom management and helps coping with the disease [5, 10, 14] .
Patients rate the success of therapy higher than expected in keeping with other studies. Significant distress is caused by side effects of therapy, in particular fatigue, which underscores the importance of discussing the side effects with the patient before the start of the therapy [15, 16] .
Comparing participants at initial diagnosis to those with recurrent disease, we noted some significant differences concerning their information needs. Patients at initial diagnosis wanted to be informed more precisely about life expectancy, the duration of hospitalization and the level of qualification and experience of the treating physician. Patients with recurrent disease prefer not to be informed in detail about a negative prognosis and measure the success of therapy on the course of the tumor marker. Interestingly, concordant to previous studies, 50, 8% of patients with recurrent disease stated to hope for full recovery [17] [18] [19] [20] . These results reflect the high need of more explanation of the palliative situation, since this misperception of their prognosis can influence treatment choices of patients. Overall, the results of this survey indicate similarities of both patient populations and show that patients with ovarian cancer have consistently high unmet needs of psychological and physical support [21, 22] .
Taking a closer look on the different age groups, younger patients have higher expectations of full recovery and need more information regarding all aspects of treatment, while for all age groups the most important information source is the treating physician. Although younger patients appear to be a more demanding, the needs of elderly patients with ovarian cancer should not be neglected. While several studies reported conflicting results suggesting that older patients required less information [4, [19] [20] [21] 23 ], we could not confirm this and suggest further studies.
Overall, studies like the presented one provide an insight into the unmet needs and expectations of patients and will help us to improve the standard of care for all women with ovarian cancer.
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